Company / Operating Cash Flow per Share
Denali Therapeutics Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.86
FY2025
5-year range
-$2.86 / $3.40
FY2021-FY2025
Trend
-13.9%
vs FY2024
Sector context
#167 of 212
Health Care
What the data says
Denali Therapeutics Inc.'s operating cash flow per share of $-2.86 is lower than 79% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-11.19 in FY2016 to $3.40 in FY2022.
Based on SEC 10-K filings.
-2.86 in FY2025.
Declined from $-2.63 to $-2.86 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-154.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 13.9% year-over-year.
- Ranks #167 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.86 | -13.9% |
| FY2024 | -$2.51 | +4.6% |
| FY2023 | -$2.63 | -177.4% |
| FY2022 | $3.40 | +370.6% |
| FY2021 | -$1.26 | -341.4% |
| FY2020 | $0.52 | +164.4% |
| FY2019 | -$0.81 | +1.5% |
| FY2018 | -$0.82 | +83.9% |
| FY2017 | -$5.12 | +54.2% |
| FY2016 | -$11.19 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026